Search Within

Alexander Paul Boardman

Formats
  1. Meeting Abstract (30)
  2. Journal Article (10)
  3. Research Letter (2)
  4. Conference Paper (1)
  5. Editorial (1)
Groups
  1. GME, Medicine (44)
  2. Graduate Medical Education (44)
  3. Hematology-Oncology Fellows (44)
  4. Department of Medicine (42)
  5. Hematologic Malignancies, Division of (41)
  6. Center for Hematologic Malignancies (40)

More Groups

People
  1. Gilles Salles (33)
  2. Maria Palomba (33)
  3. Lorenzo Falchi (23)
  4. Paola Ghione (20)
  5. Santosha Vardhana (19)
  6. Alison Moskowitz (18)

More People

Years
  1. 2025 (7)
  2. 2024 (26)
  3. 2023 (9)
  4. 2022 (2)
Publications
  1. Blood (27)
  2. Journal of Clinical Oncology (3)
  3. Blood Advances (2)
  4. International Journal of Radiation Oncology, Biology, Physics (2)
  5. Blood Cancer Journal (1)
  6. Cancer Drug Discovery and Development (1)

More Publications

Publishers
  1. American Society of Hematology (29)
  2. American Society of Clinical Oncology (3)
  3. Elsevier Inc. (3)
  4. Nature Publishing Group (2)
  5. American Association for Cancer Research (1)
  6. American Medical Association (1)

More Publishers

Results (44)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab and involved site radiation therapy alone as an alternative to transplant in patients with localized failure following chemotherapy for Hodgkin Lymphoma: A prospective multicenter phase II study
    Meeting Abstract

    Dreyfuss, A.; Ganesan, N.; Alencar, A. J.; Boardman, A. P.; Caron, P.; Chang, T.; Davey, T.; David, K. A.; Dogan, A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Improved outcomes for primary refractory classical Hodgkin Lymphoma: A retrospective analysis
    Meeting Abstract

    Santarosa, A. M.; Ganesan, N.; Chang, T.; Hannigan, K.; Casper, E.; Shah, G. L.; Boardman, A. P.; Caron, P.; David, K. A.; Dogan, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschênes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of efficacy and safety outcomes for lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) for the treatment of third-line or later (3L+) relapsed or refractory (R/R) follicular lymphoma (FL)
    Meeting Abstract

    Boardman, A. P.; Reguera, J. L.; Spin, P.; Wang, P.; Almuallem, L.; Ellis, J.; Zheng, J.; Kumar, J.; Farazi, T.; García-Sancho, A. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world outcomes of frontline polatuzumab and impact of frailty in older adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Iyengar, V.; Chicola, J.; Joseph, A.; Okwali, M.; Truong, R.; Bapodra, N.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Effector differentiation and exhaustion attenuate on-target, off-tumor toxicity of CD24 CAR T cells
    Meeting Abstract

    Boardman, A. P.; Rajagopalan, A.; Chen, S.; Ng, B.; Fischman, J.; Massa, A.; Elias, H. K.; Manuele, D.; Atmane, M. I.; Miranda, I.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High grade B-cell lymphoma with MYC/BCL6-rearrangements (R) may have inferior outcomes compared to BCL2-R disease
    Meeting Abstract

    Healton, S. E.; Luttwak, E.; Rivas-Delgado, A.; Boardman, A. P.; Caron, P.; David, K. A.; Epstein-Peterson, Z. D.; Falchi, L.; Ghione, P.; Hamlin, P. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save